The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Gender and the Progression of Renal Disease
Abstract
Background Heart involvement is common in Systemic Sclerosis (SSc), even if often clinically silent, and represent one of the leading cause of death in these patients. Objectives The aim of our study was to define the role of cardiac troponin T (cTnT) and NT-proBNP to identify cardiac involvement in SSc. Methods From 2008 to 2013 high sensitivity cTnT and NT-proBNP were measured in 200 consecutive SSc patients and in 30 sex and aged matched healthy controls. Data regarding disease subtype and organ involvement were available for the entire cohort. All SSc-related deaths were registered. Results cTnT levels and NT-proBNP values were higher in scleroderma patients (cTnT: 0.03±0.006 ng/ml and NT-proBNP: 898.8±3063.8 pg/ml) than in healthy controls (cTnT: 0.006±0.0004 ng/ml and NT-proBNP: 90.6±70.9 pg/ml, p<0.00001 for both comparisons). cTnT levels were upper the normal limit in 79 SSc patients (39.5%), 54 of whom (68.4%) complained cardiac symptoms, while 25 (31.6%) were asymptomatic. NT-proBNP levels were above the cut-off limit of 125 ng/ml, recommended by the manufacturer, in 79 patients (39.5%) and 51 presented also increased levels of cTnT. The levels of NT-proBNP directly correlate with the cTnT levels (R=0.4; p<0.0001) and were higher in patients with increase of cTnT (2154.1±4691.8 pg/ml) compared to patients without cTnT increase (115.5±145.4 pg/ml; p<0.0001).During the follow-up, 18 SSc-related death occurred; 10 of these were directly related to cardiac involvement (sudden cardiac death or heart failure, related and unrelated to pulmonary arterial hypertension) and all occurred in patients with increased cTnT levels and NT-proBNP>125 pg/ml. Cumulative survival estimated by Kaplan-Mayer curve was worse in patients with increased baseline levels of cTnT and NT-proBNP. Died patients presented higher levels of cTnT (0.11±0.03 ng/ml) and of NT-proBNP (7193.1±5691.6 pg/ml) and lower left ventricular-ejection fraction (LV-EF) (52.5±11.9%) than survivors (cTnT: 0.02±0.05 ng/ml; NT-proBNP: 585.8±2517.3 pg/ml; LV-EF: 61.9±6.6%; p<0.001 for all comparisons). At ROC curve, cTnT>0.019 ng/ml showed the best specificity (75%) with a sensitivity of 100% to identify patients with poor outcome (AUROC=0.90, p<0.0001), while the best threshold for NT-proBNP to identify patients at risk of cardiac death was 618 pg/ml, with a specificity of 90% and a sensitivity of 100% (AUROC=0.97, p<0.0001). Considering all SSc cohort, 25 patients (34.2%) presented NT-proBNP>618 mg/dl and an increase of cTnT with respect to only 2 patients (1.7%) with increased of NT-proBNP but without cTnT elevation (p<0.0001). Conclusions cTnT and NT-proBNP should be routinely evaluated in all SSc patients, even if asymptomatic, in order to identify at early stages those with a subclinical heart disease and a bad cardiac outcome. Patients with cTnT>0.019 ng/ml and NT-proBNP >618 pg/ml have an high risk of cardiac death and need to be strictly monitored. Disclosure of Interest None declared
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Estrogen Replacement Therapy on the Renin-Angiotensin System in Postmenopausal Women
Schunkert, H., Danser, A. H. J., Hense, H.-W., Derkx, F. H. M., Ku¨rzinger, S., & Riegger, G. A. J. (1997) · Circulation · doi:10.1161/01.cir.95.1.39 · Cited by 438
Estrogen regulation of angiotensin-converting enzyme mRNA
Gallagher, P. E., Li, P., Lenhart, J. R., Chappell, M. C., & Brosnihan, K. B. (1999) · Hypertension · doi:10.1161/01.hyp.33.1.323 · Cited by 290
Suppressive effects of estradiol on dimethylnitrosamine-induced fibrosis of the liver in rats
Yasuda, M., Shimizu, I., Shiba, M., & Ito, S. (1999) · Hepatology · doi:10.1002/hep.510290307 · Cited by 283
Impact of gender on the renal response to angiotensin II
Miller, J. A., Anacta, L. A., & Cattran, D. C. (1999) · Kidney International · doi:10.1046/j.1523-1755.1999.00260.x · Cited by 255
Sealey, J. E., Itskovitz-Eldor, J., Rubattu, S., James, G. D., August, P., Thaler, I., Levron, J., & Laragh, J. H. (1994) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.79.1.8027239 · Cited by 115
Cited by
Obesity and Risk for Chronic Renal Failure
Ejerblad, E., Fored, C. M., Lindblad, P., Fryzek, J., McLaughlin, J. K., & Nyrén, O. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005060638 · Cited by 680
Eriksen, B. O., & Ingebretsen, O. C. (2006) · Kidney International · doi:10.1038/sj.ki.5000058 · Cited by 576
Ix, J. H., Shlipak, M. G., Chertow, G. M., & Whooley, M. A. (2007) · Circulation · doi:10.1161/circulationaha.106.644286 · Cited by 326
Sex-Related Disparities in CKD Progression
Ricardo, A. C., Yang, W., Sha, D., Appel, L. J., Chen, J., Krousel-Wood, M., Manoharan, A., Steigerwalt, S., Wright, J., Rahman, M., et al. (2019) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018030296 · Cited by 291
Let’s talk about sex: Differences in drug therapy in males and females
Madla, C. M., Gavins, F. K. H., Merchant, H. A., Orlu, M., Murdan, S., & Basit, A. W. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.05.014 · Cited by 167
Metadata
- Authors
- Neugarten, J.
- Venue
- Journal of the American Society of Nephrology
- Published
- 2002-11
- Volume
- 13
- Issue
- 11
- Pages
- 2807-2809
- ISSN
- 1046-6673 (ISSN-L)
- OpenAlex
- W2105364102
- Cited by
- 187
- References
- 5
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Gender and the Progression of Renal Disease. https://app.cochat.ai/papers/10.1097/01.asn.0000035846.89753.d4
- The paper
- Neugarten, J. (2002). Gender and the Progression of Renal Disease. Journal of the American Society of Nephrology. https://doi.org/10.1097/01.asn.0000035846.89753.d4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.